The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Since its establishment in 1990, the ABE program has now reached over 1 million students across 16 countries, helping to ...

Amgen posted earnings that were better than expected last month. Because Amgen stock has heavy institutional ownership, this ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024 ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.